Ewing sarcoma A673 cells, TK216-resistant clones
收藏NIAID Data Ecosystem2026-03-13 收录
官方服务：
资源简介：
TK216 is in phase II clinical trials for the treatment of Ewing sarcoma, although the mechanism of action in cells is still unknown. These samples are from a forward genetic screening using MMR-deficient A673 cells to identify the mechanism of action of TK216 in cells.
创建时间：
2022-06-03
